Targeting Beta Amyloid: A Clinical Review of Immunotherapeutic Approaches in Alzheimer's Disease

Table 1

Active immunotherapy agents.

Drug name	Sponsor(s)	Mechanism of action	Status	Key clinical data	Source of key clinical data
ACC-001 (vanutide cridificar)	JANSSEN Alzheimer Immunotherapy Research & Development, LLC.; Pfizer Inc.	Multiple copies of Aβ 1-7 peptide linked to a nontoxic variant of diphtheria toxin	Phase 2	No clinical data have been presented to date	—
AD02	AFFiRiS AG	Short (6 aa) peptide mimicking parts of the native Aβ N-terminus sequence	Phase 2	Phase 1 safety data support proof-of-concept for improved safety profile using AFFITOPE technology	[48]
CAD106	Novartis, Inc.	Aβ 1-6 peptide coupled with Qβ carrier	Phase 2	In a phase 2a study, CAD106 showed a favorable safety profile and antibody response in 20/22 patients with mild AD	[45]
V950	Merck & Co.	Multivalent Aβ vaccine	Phase 1	No clinical data have been presented to date	—

Aβ: beta amyloid; AD: Alzheimer’s disease.